Treatment of X-linked hypohidrotic ectodermal dysplasia with a fusion EDA1 protein
US9925239B2 · kind B2 · utility
0Cited by
4References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 22, 2015 |
| Grant date | Mar 27, 2018 |
| Priority date | — |
| Expiry date | Sep 22, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.